On October 6, 2025 Nanoligent reported the completion of a €12 million Series A financing round led by Inveready (Inveready Biotech IV), with participation from CDTI (through the Innvierte program), Clave Capital (Clave Innohealth), and existing investors i&i Biotech Fund I, Italian Angels for Growth / Nanolinvest, and AVANTECA Partners (Press release, Nanoligent, OCT 6, 2025, https://www.nanoligent.com/nanoligent-closes-12-million-series-a-financing-to-advance-its-lead-oncology-nanodrug/ [SID1234656462]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The proceeds will support completion of the regulatory preclinical package for the company’s lead candidate, NNL1524, enable manufacturing scale-up, and fund the initiation of a Phase Ia clinical study in patients with solid tumors.
NNL1524 is a multivalent cytotoxic nanoparticle designed to selectively target the chemokine receptor CXCR4, a protein involved in tumor growth, invasion, and metastasis, and frequently overexpressed in several hematologic and solid malignancies including colorectal, lung, and breast cancers. In preclinical studies, NNL1524 demonstrated significant antitumor activity as a single agent and a favorable safety profile, supporting its advancement into clinical development.
Dr. Montserrat Cano, Chief Executive Officer of Nanoligent, commented:
"This financing represents an important milestone for Nanoligent. The support of such a strong syndicate of investors will be instrumental as the company progresses toward clinical validation of its technology and first-in-human studies."
Antonio Herce, Director of Investments at Inveready, stated:
"Nanoligent’s nanodrug platform offers a distinctive approach to targeted cytotoxic therapy, combining high selectivity, internalization efficiency, and stability. We are pleased to support the company’s efforts to bring this promising technology closer to patients."
The transaction was advised by Hoffmann Eitle and VentureTech Audit.